Swiss Medica Inc. Raghu Kilambi, C.A., Chief Executive Officer

1. Swiss Medica Inc. • Raghu Kilambi, C.A., • Chief Executive Officer (OTCBB: SWME) PATENTED, CLINICALLY TESTED, OVER-THE-COUNTER, NATURAL CHRONIC AILMENT SOLUTIONS EUROPE 2005 confidential

2. Disclaimer • Statements in this release that relate to future plans, events or performance are forward-looking statements reflecting management's current expectations, assumptions and estimates of future performance and economic conditions. All forward-looking statements are made in reliance on the safe harbor provisions of the Securities Act of 1933 and the Securities Exchange Act of 1934. The company cautions investors that forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those expressed or implied in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. • The estimates and statements contained in this presentation were prepared on the basis of assumptions and hypotheses which the Company believes to be reasonable but which are subject to substantial risks, uncertainties and contingencies, some of which are difficult to predict and beyond the control of the Company, and which may result in substantial modifications. No assurance can be given as to the availability of any of the potential benefits described in this presentation and such information should not be construed as a representation or prediction that the Company will achieve or is likely to achieve any particular results. • The assumptions and projections have neither been compiled, reviewed, nor audited by the Company’s independent certified public accountants and do not constitute a “Financial Forecast” or a “Projection” as defined by the American Institute of Certified Public Accountants. All figures used in the presentation are in US dollars. confidential

3. Strategic Opportunity • Highlights • Patented, Clinically -Tested All Natural Over-The-Counter products • Elite OTC chronic ailment solutions NOT vitamins / supplements • 3 Products targeting multi-billion $ pain relief and anti-depression markets • Replace / reduce the use of prescription and OTC products with side effects • Penetration in 19,000 doors and growing in leading North American retailers confidential

4. Industry Market ShareChronic Pain Market • 350 million adults worldwide suffer from Arthritis and chronic pain, in some form. In the United States alone: • 45 million + suffer from Osteoarthritis • 10 million + suffer from Fibromyalgia • 5 million + suffer from Rheumatoid Arthritis • 65 million Americans suffer from back pains and aches every year. Four of five adults will suffer back pain at some point in their lifetime. • Aging population will increase incidence of arthritic conditions. • Additional conditions: Gout, Tendonitis, injuries, back pain, foot pain, neck pain, shoulder pain, etc Chronic Pain Suffers (percentage) confidential

5. Industry Market ShareChronic Pain Remedies Market • In 2004, the worldwide market for pain relief products was estimated at $30 billion. • Dominated by Rx/OTC pills • Prescription pills $23 billion • OTC pills $7 billion • Consumers increasingly concerned about side effects and mixing prescription medications. • Consumers increasingly desire to self-treat pain relief and other conditions. Estimated Worldwide Pain Relief Remedies(percentage) confidential

6. Drug Industry ConcernsTroubles in $18 Billion Chronic Pain Market • September 30, 2004: Merck & Co. withdraws Vioxx® • Leading prescription pain pill: $2.5 billion revenues. • April 7, 2005: FDA requests that Pfizer withdraw Bextra® from the market • Also, requires Pfizer to include a boxed warning in the Celebrex label. • July 22, 2005: PAIN MEDICINE; Survey on physician perception of Cox-2 Inhibitors • In the wake of the withdrawal of Vioxx and Bextra from the market, fewer than one in five primary care physicians plan to prescribe COX-2 Inhibitors for treating chronic pain according to a nationwide survey by Pri-Med Institute. • April 7, 2005, The FDA required that the package insert of all NSAIDs (excluding aspirin) be revised to include a “boxed” or serious warning to highlight the potential increase risk of cardio-vascular events. • Pain Relief Market has new window open for a safe, natural topical alternative confidential

7. US-Patented, all natural, essential oil topical pain relief product line 7 essential oils, patented binding process that eliminates artificial binders that reduce absorption and efficacy Proven relief World class sports and medical endorsements from Europe, USA and Canada Extensive hospital, physician, pain clinic, chiropractor use Medical & Double-Blind Clinical studies from Europe and North America Previously used in Europe for athletes and doctors/hospitals 2 products: O24 Pain Neutralizer and O24 Fibromyalgia O24 Overview confidential

8. O24 – Natural IngredientsPatented binding process – No chemicals confidential

9. O24 Medical Studies confidential

10. Competitive Product TypesO24 vs Other Pain Relief Products • O24OTCDrugs • Patented √ √ • All Natural √ • Lasting Relief √ √ • Medical Studies √ √ √ • Endorsements √ √ √ • No Side Effects √ • Economical √ √ • Fast Acting √ confidential

11. Retail DistributionCurrently in more than 19,000 stores confidential

12. Swiss Medica Quarterly Store CountCurrently > 19,000 stores confidential

13. O24 Fibromyalgia • Fibromyalgia syndrome (FMS) is estimated to affect between 2 to 4% of the world's population • Is the second most commonly diagnosed disorder in rheumatology clinics, second only to osteoarthritis • An estimate 10-million American have been diagnosed with Fibromyalgia • Widespread and Chronic Pain • Often effects all parts of the body • Deep muscular aching, throbbing, twitching, stabbing and shooting pain • Symptoms include: • Pain, including tenderness on pressure points • Fatigue • Sleep Disorders • Headaches • Current pain treatment include acetaminophen or ibuprofen • No other clinically tested product available in North American pharmacies confidential

14. O24 Fibromyalgia • O24 Fibromyalgia is the FIRST product marketed specifically for Fibromyalgia pain to be available in North American pharmacies. It is a patented formula made from seven essential oils and has been clinically tested and shown to be an effective and safe pain reliever. • O24 Fibromyalgia is the FIRST and only product to earn the coveted National Fibromyalgia Association’s Seal of Approval. The NFA has 2,000 affiliated support groups and sphere of influence of 1 million people. • A double-blind clinical study conducted at University of Toronto found that 90 percent of patients who used O24 Fibro reported mild to markedly better improvement versus only 7 percent who were given a placebo. A full 54 percent reported moderate to markedly better improvement • Launches in North American pharmacies and retailers in fourth quarter 2005. confidential

15. O24 Fibromyalgia – Q4 LAUNCH confidential

16. Industry Market Share Anti-Depressant Market • 28 million people in the US have taken an anti-depressant • 400+ million adults worldwide suffer from some form of depression • Worldwide drug market for depression treatment is more than $17 billion: • Prescription Drugs – • 90% of the market (significant side effects) • OTC Products – • 10% of the market (no proven treatments) • Swiss Medica will launch safe, clinically proven alternatives to current Drugs and OTC products Worldwide $17 billion Anti-Depression Market (percentage) confidential

17. PMS Escape Market Opportunity • 200 million women worldwide suffer from mood and appetite symptoms associated with Premenstrual Syndrome (PMS) • PMS Escape is the only clinically proven OTC product to address these conditions • 100% drug-free • Pleasant tasting powered drink mix • Carbohydrate / nutrient blend • PMS mood market opportunity is estimated at more than $2 billion • World Class inventors of PMS Escape also invented Serafem, the only prescription drug for PMS mood symptoms • Swiss Medica’s newly acquired ADBSI division will address the PMS market and expand to anxiety and stress related treatments PMS Intensity Level(percentage) confidential

18. PMS ESCAPE confidential

19. PMS Escape: World-Class Clinical Studies confidential

20. Senior Management • Raghu Kilambi, C.A., Chief Executive Officer, Co-Founder Chartered Accountant, seasoned executive and merchant banker Co-founder of FutureLink, raised US$225 million of equity and built a $140 million revenue business with a peak market cap of $2 billion Grant Johnson, President & COO, Co-Founder Seasoned operational & sales executive with a strong track record in selling consumer products & services; Experienced in building sales and delivery teams Bruce Fairbairn, Chief Financial Officer Operational finance at Canadian subsidiaries of NYSE-listed companies including CFO of both public and private Companies Thomas Quinn, Executive Vice President, US Operations Extensive experience in sales management and product launches with pharmaceutical and consumer packaged goods leaders including Procter and Gamble and Warner Lambert confidential

21. Senior Management • Robert Esson, VP Robert Logistics and Supply Chain ManagementSenior Operations and Logistics executive with experience in consumer products (Quaker Oats) & cosmetics (BeautiControl Cosmetics). • Wendy Kramer, Vice President Anti-Depression Biohealth • Extensive background in generating new business for pharmaceutical and consumer healthcare Companies including Allegan, Inc. Mead Johns Johnson Laboratories and Warner Lambert/Parke Davis. • Rob Klein, Vice President Strategy • 10+ years in strategic planning, budgeting, financing and business development for various technology companies. In addition, was a ranked stock analyst covering Canadian Internet technology sector. • Anne Dundon, Vice President Canadian Sales • Strong consumer marketing experience in both consumer packaged goods (Proctor & Gamble, Revlon, and Bonnie Bell) and healthcare (Merck). confidential

22. Sales and Marketing Strategy confidential

23. Product Sampling confidential

24. PR oriented Radio Marketing confidential

25. Print Endorsements of O24 confidential

26. O24 in the News confidential

27. Manufacturing & Regulatory Standards • Using FDA-certified contract manufacturers to manufacture O24 and PMS Escape • USA Regulatory: • O24 Classified as OTC drug: oversight of FDA/FTC • FDA monograph controls O24 claims • PMS Escape is approved for sale in the United States under the DSHEA regulations (Dietary Supplement) • Canada Regulatory: • OTC: Health Canada • NHP registration for O24 and PMS Escape confidential

28. Growth Strategy • Enhance Product Portfolio: • Depression, stress product (organic) • Cholesterol, Diabetes, Heart Ailments • Professional Channel Distribution: • Pain Clinics, Chiropractors, hospitals, other professionals • Physician, Pharmacist Detailing: • Trade shows, samplers, conference speakers • International Distribution: • Insurance Reimbursement confidential

29. Summary • Elite, Patented, Clinically-Tested Natural Products for Chronic Ailments • Drug /OTC Pain Relief & Depression markets have major side effect concerns • Huge opportunity to capitalize on concerns about drug safety • Expanding North American national retail presence • Robust marketing campaign focused on sampling and public relations • Growth from Professional Channels, additional products, international distribution, insurance reimbursement • Strong management team with significant experience • Significant revenue growth / EBITDA positive by Q4 2005 • Sept 26th Market Cap: US$20million confidential

30. Comparable Valuations confidential

31. Contact • Contact • Chief Executive Officer: • Raghu Kilambi(416) 362-5775rkilambi@swissmedica.com • Investor Relations: • David Jones(705) 495 0022 • djones@swissmedica.com www.swissmedica.com www.O24zone.com www.pmsescape.com confidential